David A. Siegel Glycomimetics Inc Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Glycomimetics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 29,300 shares of GLYC stock, worth $9,669. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,300

Previous 165,400 82.29%

Holding current value

$9,669

Previous $390,000 77.69%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.55 - $3.49 $347,055 - $474,989	-136,100 Reduced 82.29%	29,300 $87,000
Q4 2023 Feb 14, 2024	SELL	$1.13 - $2.54 $60,567 - $136,144	-53,600 Reduced 24.47%	165,400 $390,000
Q3 2023 Nov 14, 2023	SELL	$1.29 - $1.73 $299,411 - $401,536	-232,102 Reduced 51.45%	219,000 $328,000
Q2 2023 Aug 14, 2023	SELL	$1.21 - $2.08 $173,511 - $298,267	-143,398 Reduced 24.12%	451,102 $784,000
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $503,375 - $1.63 Million	402,700 Added 209.96%	594,500 $749,000

Q4 2022 Feb 14, 2023	SELL	$0.67 - $3.03 $10,117 - $45,753	-15,100 Reduced 7.3%	191,800 $581,000
Q3 2022 Nov 14, 2022	SELL	$0.56 - $0.9 $61,880 - $99,450	-110,500 Reduced 34.81%	206,900 $114,000
Q2 2022 Aug 15, 2022	SELL	$0.54 - $1.15 $38,556 - $82,110	-71,400 Reduced 18.36%	317,400 $190,000
Q1 2022 May 16, 2022	SELL	$1.0 - $1.58 $266,000 - $420,280	-266,000 Reduced 40.62%	388,800 $443,000
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.14 $48,672 - $72,332	33,800 Added 5.44%	654,800 $943,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $158,400 - $210,320	-88,000 Reduced 12.41%	621,000 $1.36 Million
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $376,488 - $554,274	-174,300 Reduced 19.73%	709,000 $1.65 Million
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $276,573 - $403,854	95,700 Added 12.15%	883,300 $2.66 Million
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $1.24 Million - $1.96 Million	462,300 Added 142.11%	787,600 $2.96 Million
Q3 2020 Nov 16, 2020	BUY	$3.07 - $5.0 $18,420 - $30,000	6,000 Added 1.88%	325,300 $999,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $238,960 - $436,160	116,000 Added 57.06%	319,300 $1.2 Million
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $275,781 - $815,287	150,700 Added 286.5%	203,300 $464,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $211,978 - $341,900	52,600 New	52,600 $278,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

36.8M

Call Options Held

969K

Put Options Held

636K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $17.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account